Literature DB >> 33875760

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.

Edwin Roger Parra1, Maria C Ferrufino-Schmidt2, Auriole Tamegnon2, Jiexin Zhang3, Luisa Solis2, Mei Jiang2, Heladio Ibarguen2, Cara Haymaker2, J Jack Lee4, Chantale Bernatchez5, Ignacio Ivan Wistuba2.   

Abstract

Multiplex immunofluorescence (mIF) has arisen as an important tool for immuno-profiling tumor tissues. We updated our manual protocol into an automated protocol that allows the use of up to seven markers in five mIF panels to apply to formalin-fixed paraffin-embedded tumor tissues. Using a tyramide signal amplification system, we optimized five mIF panels that included cytokeratin to characterize malignant cells (MCs), immune checkpoint markers (i.e., PD-L1, B7-H3, B7-H4, IDO-1, VISTA, LAG3, ICOS, TIM3, and OX40), tumor-infiltrating lymphocytic markers (i.e., CD3, CD8, CD45RO, granzyme B, PD-1, and FOXP3), and markers to characterize myeloid-derived suppressor cells (i.e., CD68, CD66b, CD14, CD33, Arg-1, and CD11b). To determine analytical reproducibility and the impact of those panels for immuno-profiling tumor tissues, we performed an exploratory analysis in a set of non-small cell lung cancer (NSCLC) samples. The slides were scanned, and the different cell phenotypes were quantified by simultaneous co-localizations with the markers using image analysis software. Comparison between the time points of staining showed high analytical reproducibility. The analysis of NSCLC cases showed an immunosuppressive microenvironment with PD-L1/PD-1 expression as a predominant axis. Interestingly, high density of MCs expressing B7-H4 was correlated with recurrence. Unexpectedly, MCs expressing OX40 were also detected, and those cells were a closer distance to CD3+T-cells than were MCs expressing other immune checkpoints. Two different cellular patterns of spatial distribution were determined according the CD3 distribution, and the predominant pattern was related with active immunosuppressive interaction with MCs. Our study shows that these five mIF panels can identify multiple targets in a single cell with high reproducibility. The study of different cell populations and their spatial relationship can open new ideas for therapeutic approaches.

Entities:  

Year:  2021        PMID: 33875760     DOI: 10.1038/s41598-021-88156-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  41 in total

1.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

2.  Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Authors:  Mark A J Gorris; Altuna Halilovic; Katrin Rabold; Anne van Duffelen; Iresha N Wickramasinghe; Dagmar Verweij; Inge M N Wortel; Johannes C Textor; I Jolanda M de Vries; Carl G Figdor
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 3.  Immune checkpoint inhibitors for cancer treatment.

Authors:  Junsik Park; Minsuk Kwon; Eui-Cheol Shin
Journal:  Arch Pharm Res       Date:  2016-10-21       Impact factor: 4.946

Review 4.  The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Authors:  Andrew W Hahn; David M Gill; Sumanta K Pal; Neeraj Agarwal
Journal:  Immunotherapy       Date:  2017-06       Impact factor: 4.196

Review 5.  Recent developments in multiplexing techniques for immunohistochemistry.

Authors:  Angela R Dixon; Cédric Bathany; Michael Tsuei; Joshua White; Kate F Barald; Shuichi Takayama
Journal:  Expert Rev Mol Diagn       Date:  2015-08-06       Impact factor: 5.225

Review 6.  Multiplex Immunofluorescence Assays.

Authors:  Alejandro Francisco-Cruz; Edwin Roger Parra; Michael T Tetzlaff; Ignacio I Wistuba
Journal:  Methods Mol Biol       Date:  2020

Review 7.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

Review 8.  Development of immune checkpoint therapy for cancer.

Authors:  Jill M Fritz; Michael J Lenardo
Journal:  J Exp Med       Date:  2019-05-08       Impact factor: 14.307

9.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors:  Matthew D Hellmann; Luis Paz-Ares; Reyes Bernabe Caro; Bogdan Zurawski; Sang-We Kim; Enric Carcereny Costa; Keunchil Park; Aurelia Alexandru; Lorena Lupinacci; Emmanuel de la Mora Jimenez; Hiroshi Sakai; Istvan Albert; Alain Vergnenegre; Solange Peters; Konstantinos Syrigos; Fabrice Barlesi; Martin Reck; Hossein Borghaei; Julie R Brahmer; Kenneth J O'Byrne; William J Geese; Prabhu Bhagavatheeswaran; Sridhar K Rabindran; Ravi S Kasinathan; Faith E Nathan; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 10.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

View more
  5 in total

Review 1.  Multi-target combinatory strategy to overcome tumor immune escape.

Authors:  Yingyan Yu
Journal:  Front Med       Date:  2022-04-04       Impact factor: 4.592

Review 2.  Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research.

Authors:  Frank Rojas; Sharia Hernandez; Rossana Lazcano; Caddie Laberiano-Fernandez; Edwin Roger Parra
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

3.  Identification of Novel Tumor Microenvironment Regulating Factor That Facilitates Tumor Immune Infiltration in Cervical Cancer.

Authors:  Jingjing Xu; Zhe Huang; Yishu Wang; Zhenxian Xiang; Bin Xiong
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

4.  Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates.

Authors:  Shailbala Singh; Leticia C Clemente; Edwin R Parra; Amanda Tchakarov; Chao Yang; Yisheng Li; James P Long; Cassian Yee; Jamie S Lin
Journal:  Oncoimmunology       Date:  2022-09-22       Impact factor: 7.723

Review 5.  Methods to Determine and Analyze the Cellular Spatial Distribution Extracted From Multiplex Immunofluorescence Data to Understand the Tumor Microenvironment.

Authors:  Edwin Roger Parra
Journal:  Front Mol Biosci       Date:  2021-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.